Pfizer Earnings Preview: Cost-Cutting To Offset Patent Losses

In terms of therapeutic areas, we expect cancer drugs to do well, as the pressure on cardiovascular sales continues. Geographically speaking, emerging markets will be in focus due to the expected volume growth driven by sales of Prevenar.